Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, Hosoda S, Yoshida S, Kubo A, Fu Q, Yang Z, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Kobayashi T, Tsunematsu I, Sakamoto N. Suda G, et al. Among authors: kubo a. J Med Virol. 2023 Feb;95(2):e28452. doi: 10.1002/jmv.28452. J Med Virol. 2023. PMID: 36597900
Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19.
Suda G, Ogawa K, Kimura M, Maehara O, Kitagataya T, Ohara M, Tokuchi Y, Kubo A, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Sakamoto N. Suda G, et al. Among authors: kubo a. Hepatol Res. 2020 Oct;50(10):1196-1200. doi: 10.1111/hepr.13551. Epub 2020 Aug 14. Hepatol Res. 2020. PMID: 32729953
Durable response without recurrence to Tolvaptan improves long-term survival.
Nakai M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Ohara M, Umemura M, Sho T, Morikawa K, Ogawa K, Sakamoto N. Nakai M, et al. Among authors: kubo a. J Gastroenterol. 2020 Dec;55(12):1150-1161. doi: 10.1007/s00535-020-01721-8. Epub 2020 Aug 26. J Gastroenterol. 2020. PMID: 32851487
Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Shigesawa T, et al. Among authors: kubo a. PLoS One. 2021 Mar 1;16(3):e0247728. doi: 10.1371/journal.pone.0247728. eCollection 2021. PLoS One. 2021. PMID: 33647018 Free PMC article.
Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.
Kawagishi N, Suda G, Kimura M, Maehara O, Yamada R, Tokuchi Y, Kubo A, Kitagataya T, Shigesawa T, Suzuki K, Ohara M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Kawagishi N, et al. Among authors: kubo a. Sci Rep. 2021 Apr 28;11(1):9207. doi: 10.1038/s41598-021-88632-7. Sci Rep. 2021. PMID: 33911145 Free PMC article.
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Sho T, et al. Among authors: kubo a. Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20. Hepatol Res. 2021. PMID: 34245216
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
Kubo A, Suda G, Kimura M, Maehara O, Tokuchi Y, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Kubo A, et al. Cancers (Basel). 2021 Jul 20;13(14):3633. doi: 10.3390/cancers13143633. Cancers (Basel). 2021. PMID: 34298844 Free PMC article.
Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.
Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Ohara M, Yamada R, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Tokuchi Y, et al. Among authors: kubo a. Sci Rep. 2021 Aug 16;11(1):16616. doi: 10.1038/s41598-021-96203-z. Sci Rep. 2021. PMID: 34400736 Free PMC article.
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.
Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Fu Q, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Yang Z, et al. Among authors: kubo a. Cancers (Basel). 2022 Jan 4;14(1):232. doi: 10.3390/cancers14010232. Cancers (Basel). 2022. PMID: 35008398 Free PMC article.
1,379 results